Catalog No.
Product Name
Application
Product Information
Citations
-
Herbicide
Carfentrazone-ethyl is a selective post-emergence herbicide that acts as a protoporphyrinogen oxidase (Protox) inhibitor, exhibiting an IC50 value of 18 nM against soybean Protox. This compound effectively disrupts the biosynthesis of chlorophyll and heme, leading to the rapid death of susceptible weeds, such as ivy-leaved morning glory and velvetleaf. Its primary applications include the control of broadleaf weeds in various agricultural settings, making it a valuable tool in herbicide research and development. -
Herbicide
Atraton is a 1,3,5-triazine herbicide that exerts its activity through selective inhibition of photosynthetic processes in target plants. This compound is noted for its photodegradability, undergoing degradation when activated by the photosensitizer acetone. Atraton is primarily utilized in agricultural research to study the effects of herbicide application and its environmental fate. -
Herbicide
Buminafos is an organophosphate herbicide that targets key enzymes involved in weed growth regulation. It exhibits broad-spectrum activity against various weed species, making it valuable for enhancing agricultural productivity. This reagent is primarily used for research applications related to herbicide efficacy and the mechanisms of herbicide resistance in crops. -
Herbicide
Flupropanate is a selective herbicide that functions as a plant growth inhibitor by disrupting radicle growth and lipid biosynthesis in susceptible plants. It effectively controls Stipa weeds, including Nassella neesiana and N. trichotoma, while reducing the prevalence of the invasive species Eragrostis curvula. Flupropanate shows sensitivity to gramineous plants like ryegrass but exhibits good tolerance in species such as plantain, chicory, and some legumes. Research indicates that in Mediterranean climates, Flupropanate has minimal non-target impact on native plant communities and endangered species, demonstrating its ecological safety. -
Herbicide
Sulfosate is a post-emergence, non-selective herbicide that functions by inhibiting the synthesis of essential amino acids in plants. It effectively controls a broad spectrum of weeds through translocation, making it useful in various agricultural applications. Sulfosate is particularly valuable in the management of challenging weed populations, facilitating improved crop yield and quality. -
Herbicide
Defenuron is a selective herbicide that inhibits the growth of undesirable grasses and broad-leaved plants in various agricultural crops. Its primary mechanism targets specific biochemical pathways, effectively minimizing competition for nutrients and sunlight. Defenuron is utilized in research to study herbicidal activity and crop management strategies, contributing to the development of sustainable agricultural practices. -
Herbicide
Monisouron (SSH-41) is a selective herbicide targeting post-emergence control of a range of broad-leaved and grass weeds while preserving the integrity of crops such as barley, pea, and maize. This compound demonstrates significant herbicidal activity, making it a valuable tool for research focused on weed management strategies and agricultural applications. Its selectivity profile contributes to effective weed control in diverse crop systems. -
HMG-CoA reductase Inhibitor
Atorvastatin (lysine) is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This compound is primarily utilized in research focused on hypercholesterolemia and mixed hyperlipidemia, enabling studies on lipid regulation and cardiovascular health. Its ability to modulate cholesterol levels makes it valuable for investigating therapeutic approaches for dyslipidemia-related conditions. -
HMG-CoA Reductase Inhibitor
BMS-180431 is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound effectively reduces cholesterol biosynthesis, making it relevant for research in lipid metabolism and cardiovascular disease. It is applicable in studies exploring hyperlipidemia, atherosclerosis, and related metabolic disorders. -
HMG-CoA Reductase (HMGCR) Inhibitor
Lovastatin hydroxy acid sodium is a potent inhibitor of HMG-CoA reductase (HMGCR), exhibiting a Ki of 0.6 nM. By effectively blocking the enzymatic action of HMGCR, this compound plays a critical role in cholesterol biosynthesis regulation. It is widely utilized in research to explore lipid metabolism, cardiovascular diseases, and therapeutic interventions for dyslipidemia. -
HMG-CoA Inhibitor
Pravastatin lactone is a potent HMG-CoA reductase inhibitor that functions as a metabolite of pravastatin. It effectively decreases blood cholesterol levels by inhibiting the synthesis of cholesterol in the liver. This compound is widely used in research related to lipid metabolism, cardiovascular diseases, and the development of cholesterol-lowering therapies. -
HMG-CoA Reductase (HMGCR) Inhibitor
β-Amyrin palmitate is an HMG-CoA reductase (HMGCR) inhibitor that plays a crucial role in lipid metabolism. This compound exhibits biological activity that can aid in the management of diabetes mellitus, making it a valuable reagent for research in metabolic disorders. Its ability to modulate cholesterol biosynthesis may also offer insights into cardiovascular health and related conditions. -
HMG-CoA Inhibitor
Bemfivastatin hemicalcium is an orally active inhibitor of HMG-CoA reductase (HMGCR), targeting cholesterol biosynthesis. This compound effectively promotes the liver's ability to extract lipids, leading to a significant reduction in blood lipid levels. Bemfivastatin hemicalcium is applicable in research on metabolic disorders, particularly in studying hypercholesterolemia and related conditions. -
HMG-CoA Inhibitor
Lovastatin acid is a potent competitive inhibitor of HMG-CoA reductase, with an inhibition constant (Ki) of 0.6 nM. As an active metabolite of Lovastatin, it effectively interferes with cholesterol synthesis by inhibiting the conversion of HMG-CoA to mevalonate. This compound is particularly valuable for research into hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5S)-Pitavastatin calcium is a potent HMG-CoA reductase inhibitor effective in lowering cholesterol levels. It plays a significant role in the study of cardiovascular diseases by inhibiting lipid biosynthesis and improving lipid profiles. This compound is primarily utilized in research applications focused on atherogenesis and the investigation of statin therapy mechanisms. -
HMG-CoA Reductase Inhibitor
Rosuvastatin zinc salt is a zinc-complexed form of Rosuvastatin, an HMG-CoA reductase inhibitor. This compound effectively reduces cholesterol synthesis, making it valuable in atherosclerosis research. Its mechanism of action supports studies focusing on lipid regulation and cardiovascular disease prevention. -
HMG-CoA Reductase (HMGCR)
(3S,5R)-Fluvastatin potassium is an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This compound exhibits antioxidative properties, influencing the oxidation of LDL in the presence of copper ions, akin to its 3R,5S enantiomer. Investigations have indicated that (3S,5R)-Fluvastatin potassium and its metabolites may possess anti-atherosclerotic effects through their antioxidative activities. It is commonly employed in research focused on cholesterol regulation and cardiovascular disease mitigation. -
HMG-CoA Reductase (HMGCR)
Ganoderic acid SZ is a potent inhibitor of HMG-CoA reductase (HMGCR), demonstrating superior activity compared to atorvastatin. This natural compound also significantly inhibits α-glucosidase derived from yeast, with low nanomolar IC50 values. Additionally, Ganoderic acid SZ exhibits cytotoxic effects against K562 leukemia cells, with IC50 values ranging from 10 to 20 μM. These properties make Ganoderic acid SZ a valuable tool for research in cholesterol metabolism and cancer studies. -
HMG-CoA Reductase Inhibitor
BMS-180431 sodium is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound plays a pivotal role in cholesterol biosynthesis, making it valuable for research focused on lipid metabolism and related cardiovascular diseases. Its inhibitory effects on HMG-CoA reductase provide a useful tool for studying cholesterol-lowering interventions and the underlying mechanisms of dyslipidemia. -
HMG-CoA Reductase Inhibitor
L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. This compound significantly reduces circulating serum cholesterol levels, demonstrating its efficacy in cholesterol management. Additionally, L-645164 shows potential for use in research related to central nervous system disorders, providing new avenues for investigation into therapeutic strategies. -
HMG-CoA Reductase Inhibitor
PF-3052334 is a potent, orally available inhibitor of HMG-CoA reductase, exhibiting an IC50 of 1.9 nM. This compound selectively inhibits cholesterol synthesis in hepatocytes with an IC50 of 0.9 nM, while displaying a significantly higher IC50 of 730 nM in muscle cells. PF-3052334 serves as a valuable tool for investigating hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
SQ-33600 is an HMG-CoA reductase inhibitor that exhibits cholesterol-lowering activity. It demonstrates significant selectivity, showing a much stronger inhibitory effect on rat hepatocytes (IC50: 93 nM) compared to human skin fibroblasts (IC50: 14200 nM). This compound is valuable for research on hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
Crilvastatin is a potent HMG-CoA reductase inhibitor that plays a critical role in cholesterol biosynthesis regulation. By inhibiting this key enzyme, Crilvastatin effectively lowers cholesterol levels, making it valuable for research in dyslipidemia and cardiovascular disease. This compound serves as a useful tool in studies aimed at understanding lipid metabolism and the therapeutic potential of statins in managing hyperlipidemic conditions. -
HMG-CoA Reductase Inhibitor
(Rac)-5-Keto Fluvastatin is a specific impurity of Fluvastatin, functioning primarily as an HMG-CoA reductase inhibitor. With an IC50 value of 8 nM, it demonstrates potent inhibitory activity against this key enzyme involved in cholesterol biosynthesis. This compound is useful for studies focused on lipid metabolism and cardiovascular research, enabling the investigation of statin-related mechanisms and effects. -
HMG-CoA Inhibitor
L-669,262 is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, exhibiting an IC50 of 0.10 ng/mL in rat liver preparations. This compound effectively downregulates cholesterol synthesis, making it a valuable tool in lipid metabolism research and studies focused on cardiovascular disease. Its specificity and high potency facilitate a wide range of applications in pharmacological studies and drug development targeting dyslipidemia. -
HMG-CoA Reductase Inhibitor
Pitavastatin magnesium is a potent HMG-CoA reductase inhibitor that plays a critical role in lipid metabolism. It effectively reduces total cholesterol and low-density lipoprotein cholesterol levels, as demonstrated in hyperlipidemic rat models. This compound is valuable for research focused on cardiovascular and cerebrovascular diseases, particularly in studies investigating hyperlipidemia and its associated conditions. -
HMG-CoA Reductase (HMGCR) Inhibitor
L 668411 is a β-lactone compound that acts as an inhibitor of HMG-CoA Reductase (HMGCR), targeting cholesterol biosynthesis. It effectively inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and reduces [14C] acetate incorporation into sterols in Hep G2 cell cultures. The inhibition demonstrates an irreversible mechanism in cellular systems, while exhibiting reversible properties in cultured cells and animal models, making it a valuable tool for studying cholesterol metabolism and related diseases. -
HMG-CoA Reductase Inhibitor
Tenivastatin calcium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis. This compound has potential applications in the study of hyperlipidemia and cardiovascular disease, providing insights into lipid metabolism and associated disorders. Researchers can utilize Tenivastatin calcium to explore therapeutic strategies aimed at managing lipid abnormalities. -
HMG-CoA Reductase Inhibitor
Glenvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme critical in the cholesterol biosynthesis pathway. This compound effectively reduces plasma levels of total cholesterol and phospholipids, as well as liver cholesterol content, without increasing cholesterol or total bile acids in gallbladder bile. Glenvastatin is valuable for research focused on hyperlipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 sodium is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, (3S,5R)-Fluvastatin. This compound exhibits a potent inhibitory activity with an IC50 of 8 nM, making it valuable for studying cholesterol biosynthesis. In addition to its role in lipid regulation, Fluvastatin has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, offering insights for cardiovascular research applications. -
HMG-CoA Reductase Inhibitor
Dalvastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis. By effectively reducing cholesterol levels, Dalvastatin demonstrates significant potential in the management of hyperlipidemia and related cardiovascular conditions. Its ability to modulate lipid profiles makes it a valuable tool for research into lipid metabolism and cardiovascular disease therapeutics. -
HMG-CoA Reductase Inhibitor
GR 92549 is a potent, orally active inhibitor of HMG-CoA reductase, targeting the enzyme responsible for cholesterol biosynthesis. This compound effectively reduces cholesterol levels and may serve as a significant tool in metabolic and cardiovascular research. Its capability to modulate cholesterol metabolism makes it valuable for studies related to dyslipidemia and atherosclerosis. -
HMG-CoA Reductase (HMGCR) Control
((3R,5R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate) calcium(II) is a control compound associated with HMG-CoA reductase (HMGCR), a key enzyme involved in cholesterol biosynthesis. This compound serves as an impurity marker in the analysis of Rosuvastatin, an established HMGCR inhibitor. Its role in research applications includes evaluating batch consistency and the purity of statin formulations, facilitating the development and quality control of lipid-lowering therapeutics. -
HMG-CoA Reductase (HMGCR) Inhibitor
Rawsonol is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol biosynthesis pathway. Derived from the green alga Avrainuika rawsoni, Rawsonol demonstrates significant inhibitory activity, making it a valuable tool for research investigating cholesterol regulation and related metabolic pathways. Its role as an HMGCR inhibitor positions it for applications in studies of lipid metabolism and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Pitavastatin calcium functions primarily as an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This enantiomer exhibits significant lipid-lowering activity, making it valuable for research into dyslipidemia and cardiovascular disease. Its efficacy in modulating lipid profiles has led to its application in studies focused on metabolic disorders and therapeutic approaches for hypercholesterolemia. -
Herbicide Agent/4-HPPD Inhibitor
Benzobicyclon is an effective 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor exhibiting herbicidal properties. It hydrolyzes in the presence of water to produce the active agent benzobicycline, leading to the bleaching and subsequent death of various weed species. This reagent demonstrates efficacy against grass, sedge, and broadleaf weeds, including biotypes that are resistant to sulfonylurea herbicides, making it a valuable tool for herbicide resistance research and weed management studies. -
HPPD/PPO Dual Inhibitor
HPPD/PPO-IN-1 is a dual inhibitor targeting 4-hydroxyphenylpyruvate dioxygenase (HPPD) and protoporphyrinogen oxidase (PPO), exhibiting IC50 values of 0.12 μM and 0.51 μM, respectively, for Arabidopsis thaliana HPPD and Nicotiana tabacum PPO. This compound demonstrates broad-spectrum herbicidal activity against various weed species while maintaining safety for crops such as peanuts and cotton. HPPD/PPO-IN-1 is suitable for research focused on the development of environmentally sustainable herbicides. -
IDO1 Inhibitor
Amg-1 is a potent and reversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 3.0 μM. It demonstrates significant selectivity, with over 80-fold greater inhibition of IDO1 compared to IDO2 and over 20-fold selectivity against TDO. This compound is valuable for research in cancer, hypotension, and neurological disorders, facilitating the exploration of therapeutic strategies targeting immune regulation and metabolism. -
Apo-IDO1 Inhibitor
IDO1-IN-28 is an Apo-IDO1 inhibitor that disrupts heme binding with an IC50 of 1.29 μM. This compound selectively targets apo-IDO1, offering a valuable tool for studying its role in tumor immunology. IDO1-IN-28 is applicable in cancer research, facilitating investigations into the modulation of immune responses in various malignancies. -
IDO Inhibitor
(S)-Indoximod is a selective inhibitor of indoleamine 2,3-dioxygenase (IDO), with a Ki value of 19 μM. This compound has demonstrated notable biological activity in modulating immune responses and has potential applications in cancer research and the study of neurological disorders. Its ability to inhibit IDO activity makes it a valuable tool for investigating therapeutic strategies in various disease contexts. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-4 is a dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of 3.53 μM and 1.15 μM, respectively. It interacts with IDO1 through hydrogen bonding and engages TDO via π−π stacking interactions. This compound is valuable for investigating the role of IDO1/TDO in depression and related conditions, including infectious, metabolic, and autoimmune disorders. -
IDO1 Inhibitor
DP00477 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 7.0 µM. This compound is valuable for investigating the role of IDO1 in tumor immune evasion and has potential applications in cancer research. Its inhibitory effects can facilitate studies on the modulation of the immune response in cancer therapy. -
IDO1 Inhibitor
IDO1-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a critical enzyme in tryptophan metabolism that plays a role in immune regulation and tumor immune evasion. This compound demonstrates significant biological activity in inhibiting IDO1, which may enhance anti-tumor immune responses. IDO1-IN-18 is valuable for research applications in cancer biology and immunology, particularly in studies exploring the modulation of immune responses in tumor microenvironments. -
IDO1/IDO2 Inhibitor
IDO1/2-IN-1 is a novel dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and IDO2, with IC50 values of 28 nM and 144 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. The orally active nature of IDO1/2-IN-1 enhances its potential for in vivo studies, facilitating the exploration of immunomodulatory effects and therapeutic applications in oncology. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-9 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of less than 1 μM. This compound effectively inhibits the enzymatic activity of IDO1 and TDO, thereby blocking the degradation of tryptophan to kynurenine. By restoring immune activity within the tumor microenvironment, IDO1/TDO-IN-9 shows potential in suppressing tumor growth, making it a valuable tool for cancer research. -
IDO1 Inhibitor
4-Phenyl-1H-1,2,3-triazole is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 60 μM. This compound plays a crucial role in cancer research by modulating immune responses and inhibiting tumor-induced immune tolerance. Its ability to interfere with the kynurenine pathway makes it a valuable tool for studying tumor microenvironments and exploring new therapeutic strategies in oncology. -
IDO1 Inhibitor
BMS-986242 is a selective, orally active inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1). This compound demonstrates potent inhibition of IDO1 enzymatic activity, a critical pathway in the immunosuppressive tumor microenvironment. Research applications include exploring its use in combination therapies for cancer treatment and investigating its effects on immune response modulation. -
IDO Inhibitor
IDO2-IN-1 is a potent inhibitor of Indoleamine 2,3-dioxygenase 2 (IDO2), exhibiting an IC50 value of 112 nM. This compound is designed for use in research related to inflammatory autoimmunity, providing valuable insights into the mechanisms of immune modulation. Its ability to selectively inhibit IDO2 activity positions it as a crucial tool for exploring therapeutic strategies in related disease contexts. -
IDO Inhibitor
Kushenol E is a flavonoid derived from Sophora flavescens and acts as a non-competitive inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 7.7 µM and a Ki of 9.5 µM. This compound exhibits notable anti-tumor activity, making it relevant for research applications in cancer biology and immunotherapy. Its mechanism of action provides potential insights into immune modulation within the tumor microenvironment. -
IDO Inhibitor
IDO-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the regulation of immune responses. By inhibiting IDO, this compound enhances T-cell activity and potentially mitigates immunosuppression in the context of infectious and cancer diseases. IDO-IN-18 is instrumental in research aimed at understanding immune modulation and developing therapeutic strategies for various malignancies and chronic infections.
